The efficacy of augmentation Donepezil to risperidon in treatment of autism spectrum disorders
Not Applicable
- Conditions
- Autism Spectrum Disorders.Pervasive developmental disorders
- Registration Number
- IRCT2017041333406N1
- Lead Sponsor
- Vice Chancellor for Research of Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
The inclusion criteria: Of all patients with ASD, ranging in age from 6 to 17years; Parent's Consent; No obvious organic disease; The lack of other psychiatric disorders; Not taking other psychoactive medications other than risperidone; IQ higher than 50 on the basis of Weiland test. The exclusion criteria: In the absence of cooperation of parents after inclusion; the risk of any side effect or another disease that cause a problem in results.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to treatment. Timepoint: Previous the syudy, 6 weeks after study, 12 weeks after study. Method of measurement: CARS test.;Severity of Autism. Timepoint: Previous the syudy, 6 weeks after study, 12 weeks after study. Method of measurement: CARS test.
- Secondary Outcome Measures
Name Time Method Drug's side effect. Timepoint: Previous the study, 6weeks after study, 12weeks after study. Method of measurement: Check list.